Novartis confirmed plans for the 100% spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs (American Depositary Receipts) to commence on October 4, 2023
Sandoz announced that the FDA has accepted its Biologics License Application (BLA) under the 351(k) pathway for its proposed biosimilar...
Novartis announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off
Sandoz, announced that it will not pursue its submission for biosimilar rituximab in the US at this time. The decision...
The Sandoz application for a marketing authorisation at EMA for Zioxtenzo (pegfilgrastim biosimilar) has been withdrawn. Zioxtenzo was developed as...
Sandoz announced that the FDA has accepted its Biologics License Application for filgrastim, which was filed under the new biosimilar...
Sandoz has announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar...
Sandoz AG, a global leader in generic and biosimilar medicines, has announced the location of its future permanent headquarters in central Basel
Sandoz, a Novartis company and a global leader in biosimilars, announced that it has acquired from Pfizer the rights for...